Venenum Biodesign is dedicated to discovering small molecule therapeutics against novel targets and partnering these discoveries with pharmaceutical/biotech companies, and offering access to state-of-the-art core capabilities (assay development including protein expression and crystallography, ultra-high-throughput screening of our 5.5 million compound collection, plate production, and medicinal chemistry compound optimization) to academic institutions, research organizations and pharmaceutical companies in the US and internationally.